T. Rowe Price Associates’s Mirum Pharmaceuticals MIRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $72.1M | Buy |
1,417,215
+2,078
| +0.1% | +$106K | 0.01% | 643 |
|
|
2025
Q1 | $63.8M | Sell |
1,415,137
-7,592
| -0.5% | -$342K | 0.01% | 647 |
|
|
2024
Q4 | $58.8M | Buy |
1,422,729
+138,623
| +11% | +$5.73M | 0.01% | 704 |
|
|
2024
Q3 | $50.1M | Buy |
1,284,106
+84,886
| +7% | +$3.31M | 0.01% | 753 |
|
|
2024
Q2 | $41M | Sell |
1,199,220
-398,286
| -25% | -$13.6M | ﹤0.01% | 782 |
|
|
2024
Q1 | $40.1M | Buy |
1,597,506
+432,824
| +37% | +$10.9M | ﹤0.01% | 778 |
|
|
2023
Q4 | $34.4M | Buy |
1,164,682
+1,132,723
| +3,544% | +$33.4M | ﹤0.01% | 802 |
|
|
2023
Q3 | $1.01M | Sell |
31,959
-67,722
| -68% | -$2.14M | ﹤0.01% | 1791 |
|
|
2023
Q2 | $2.58M | Buy |
99,681
+87,753
| +736% | +$2.27M | ﹤0.01% | 1389 |
|
|
2023
Q1 | $287K | Sell |
11,928
-4,903
| -29% | -$118K | ﹤0.01% | 2365 |
|
|
2022
Q4 | $328K | Buy |
16,831
+4,800
| +40% | +$93.5K | ﹤0.01% | 2338 |
|
|
2022
Q3 | $253K | Buy |
+12,031
| New | +$253K | ﹤0.01% | 2453 |
|